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ABSTRACT
Adrenocortical cancer (ACC) is a rare aggressive malignancy. Recent ACC 
integrated genomics analysis contributed to redefine the risk groups on molecular basis, 
including tumor microRNAs (miRs), detectable also in the bloodstream. We developed 
a quantitative real-time (RT) assay for the measurement of miR483 and miR483-5p 
absolute levels in plasma samples. miR483/miR483-5p levels were evaluated in plasma 
samples of 27 patients with ACC before surgery and at follow-up.
Statistically significant differences in miR483-5p and miR483 levels were found 
between stage 1/2 and stage 3/4 ACCs in pre-surgery and post-surgery samples. ROC 
curve analysis of miR483–5p levels gave a prediction of the clinical stage (accuracy 
0.917±0.084), with the best cut-off value of 0.221 ng/ml, prognosticating overall and 
recurrence-free survival. In a multivariate Cox analysis (HR 16.2, 95%CI[1.39-188.6, 
P<0.026]), miR483-5p was the only variable that significantly predicted recurrence, 
but not overall survival. In addition, miR483 and miR483-5p levels correlated with 
the number of circulating tumor cells (CTCs) detected in the same blood samples, 
independently of the timing of sampling. In conclusion, we demonstrated that miR483-
5p absolute plasma levels in ACC patients are powerful molecular markers that may 
help in the follow-up of patients after surgery and chemotherapy, and contribute to 
more accurately classify and predict tumor progression.
INTRODUCTION
Adrenocortical carcinoma (ACC) is a rare but often 
aggressive tumor, with dismal prognosis and limited 
therapeutic options. A complete resection of the mass is 
the mainstay treatment associated with adjuvant mitotane 
therapy at advanced stages. Although mitotane mechanisms 
of action are still poorly understood, its use has been proven 
to significantly increase disease-free survival [1].
Over the last years, the diagnostic and prognostic 
relevance of the pan-genomics profile clustering of tumors 
has been demonstrated for adrenocortical cancer [2, 3]. In 
addition to the profiles derived from the analysis of the 
characteristics of the primary tumor mass, information 
provided by the liquid biopsy components, i.e. miRNA 
(miR), free circulating DNA, and circulating tumor cells 
(CTCs), can better characterize tumors at a molecular 
level [4]. The liquid biopsy is a non-invasive test on blood 
samples, and provides biological material to monitor easily 
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017
Oncotarget2www.impactjournals.com/oncotarget
the tumor progression and response to therapies. Integration 
of this molecular information enables the identification of 
subgroups of malignant tumors with distinct molecular 
alterations and clinical outcomes, enabling the possibility 
of future personalized therapeutic approaches [5].
miRs are small non-coding RNA molecules that 
modulate expression of target genes post-transcriptionally 
by degrading mRNA or inhibiting translation [6]. Different 
miR profiles have been characterized in ACC [7, 8]. In 
particular, the two mature sequences of miR483, miR483-
5p and miR483-3p, mapping in the second intron of the 
insulin-like growth factor 2 (IGF2) gene, have proved to 
be overexpressed both in the primary tumor [9-11] and the 
bloodstream [12-14], with a diagnostic and prognostic value 
[12-14]. Despite the significant association between high 
relative circulating levels of miR483 in ACC patients before 
surgery and shorter recurrence-free and overall survival, no 
attempt has been made so far to evaluate miR483 absolute 
circulating levels and their modulation during the post-
surgery follow-up.
We measured miR483 and miR483-5p absolute 
plasma levels of a cohort of 27 ACC patients before and 
after surgery, uncovering correlations with disease stage and 
predictive values particularly for the -5p variant.
RESULTS
miR483 and miR483-5p detection in cell-free 
plasma samples
Plasma samples were collected in pre-surgery 
(pre-S) and post-surgery (post-S) from a cohort of 27 
patients affected by ACC, whose clinical characteristics 
are reported in Table 1. Mean follow-up was 17.6±17.3 
months. Data was compared with that obtained by plasma 
analysis of 13 ACA patients, whose characteristics are 
shown in Table 2, and 10 healthy controls. miR483 
absolute concentration was measured in all samples by 
means of a calibration curve, and expressed as ng/ml 
of plasma. miR483 absolute expression mean values in 
pre-S and post-S from ACCs, stratified into low (stages 
1-2, St 1/2) and high (stages 3-4, St 3/4) pathologic 
stages, are displayed in Figure 1A, together with 
miR483 values from ACA and healthy control samples. 
A significant difference was found between the two stage 
groups in both miR483 values of pre-S (0.089±0.079 
ng/ml and 0.210±0.113 ng/ml, St 1/2 and St 3/4, 
P=0.016, respectively) and post-S (0.066±0.0640 ng/
ml and 0.150±0.102 ng/ml, St 1/2 and St 3/4, P=0.001, 
respectively) samples. The decrease observed in miR483 
levels between pre-S and post-S samples within each 
stage group did not reach a statistical significance, 
probably due to the high variability among patients 
and the prevalence of sampling time very close to the 
operation, when miRs derived from the mass before 
being removed may be still present in the bloodstream. 
A significant difference in miR483 levels was seen 
between pre-S values of St 3/4 ACC and those of healthy 
controls [miR483 (ng/ml): 0.105±0.049, P=0.018] or 
ACAs [miR483 (ng/ml): 0.114±0.062, P=0.014]. There 
was difference between pre-S samples of St 1/2 ACCs 
and healthy controls or ACAs.
We also assessed the absolute levels of the mature 
miR483-5p form using specific primers in samples screened 
Figure 1: miR483 and miR483-5p detection in plasma samples. miR483 (A) and mir483-5p (B) levels were measured in plasma 
samples obtained from n=27 patients with ACC, (pre surgery and post surgery), n=10 with ACA (pre-surgery) and n=10 healthy subjects. 
ACC samples were further stratified into low (st 1/2) and high (st 3/4) clinical stages, according to ENS@T classification [18]. Data is 
expressed as mean±SD of miR evaluated in the blood samples, with a follow-up median[95%CI] time from surgery of 13[4-27.5] months. 
The number of samples analyzed in each group is indicated (n). Statistics were performed with Student‘s t test for independent samples and 
P values are shown. (C) Positive correlation between miR483 and miR483-5p levels in samples from ACC patients. miR483-5p or miR483 
were measured in n=32 pre-surgery and post-surgery samples;R=0.470, P=0.006.
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for the total miR483 expression. We confirmed the presence of 
a significant difference between the two stage groups in both 
pre-S [miR483-5p (ng/ml):0.110±0.053 and 0.364±0.234, 
St 1/2 and St 3/4, P=0.002] and post-S [miR483-5p (ng/ml): 
0.100±0.053 and 0.290±0.270, St 1/2 and St 3/4, P=0.03] 
levels, Figure 1B. Similarly to miR483, the decrease observed 
in miR483-5p levels between pre-S and post-S samples was 
not statistically significant albeit stage stratification, Figure 1B. 
A significant positive correlation was identified between total 
miR483 and miR483-5p levels, Figure 1C.
Association of miR483-5p and miR483 levels with 
clinical parameters in ACC patients
When ACC clinical parameters were considered, a 
positive correlation was found between tumor stage and 
Table 1: Characteristics of ACC patients. Mean (SD) values for the indicated parameters are reported, along with 
the number (N) of patients and their percentage.
Mean (SD) N Patients %
Age at surgery (years) 45.3(16.2) 27 100
Sex
 Male 11 41
 Female 18 59
Secretion 17 63
 Cortisol 10 37
 Androgens 8 30
 DHEAS 2 7
 Progestins 1 4
Tumor Diameter (cm) 8.8(4.9) 27 100
Ki67 (%) 26.8(24.7) 25 92.6
WEISS 6.5(1.9) 24 88.9
Stage
 1 6 22
 2 12 44
 3 4 15
 4 5 19
Metastases





Surgery Resection R0 18 67
R2 5 22
nd 3 11
MTT therapy 21 78
Other Chemotherapies (EDP, taxol) 10 37
Radiotherapy 0 0
Follow-up from surgery (months) 17.6(17.3) 27 100
Survival 21 78
Etoposide-Doxorubicin-Cisplatin combined chemotherapy (EDP), Mitotane (MTT), not described (nd)
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pre-S miR483-5p and miR483 levels (R=0.567, P=0.022, 
n=16, and R=0.527, P=0.036, n=16, respectively). Tumor 
diameter was only associated with pre-S miR483 levels 
(R=0.627, P=0.005, n=18,). There was no correlation with 
either Ki67% or Weiss score, even when stratifying ACC 
into two groups according to Ki67% value and Weiss score 
(cut-off of 10% for Ki67% and 6 for the Weiss score).
Diagnostic and prognostic power of miR483-5p 
absolute plasmatic levels
ROC curve analysis was applied to assess the 
diagnostic accuracy of miR483 to distinguish between the 
low and high ACC stages. Better accuracy was achieved 
when considering pre-S miR483-5p levels (AUC of 
Table 2: Characteristics of ACA patients. Mean (SD) values for the indicated parameters are reported, along with 
the number (N) of patients and their percentage.
Mean (SD) N Patients %
Age at diagnosis (years) 57.4(15.2) 13 100
Sex
 Male 5 38
 Female 8 67
Secretion
 Cortisol 6 46
 Non sec 7 54
Tumor Diameter (cm) 3.6(1.2) 13 100
Follow-up surgery/diagnosis (months) 30.7(16.8) 13 100
Surgery 7 54
Survival 13 100
Figure 2: Receiver Operator Characteristics (ROC) and Kaplan-Meier (KM) analysis for miR483 and miR483-5p 
absolute levels in ACC patients. ROC curve for miR483-5p (A) and miR483 (B) levels to discriminate between low (St1/2) and high 
(St3/4) clinical stages in ACC are shown. The ROC curve represents the relation between specificity and sensitivity for different thresholds 
miR (continuous line) compared to the diagonal reference line (dotted line). The area under the curve (AUC) represents the accuracy of the 
analysis, indicated with its SD. Kaplan–Meier survival analysis for circulating miR483-5p levels: (C) Recurrence free survival: miR483-5p 
levels ≥ 0.221 ng/ml cut off value derived from the ROC analysis are associated with a significantly lower recurrence free survival (Log 
Rank, P=0.027). (D). Overall survival: miR483-5p levels ≥ 0.221 ng/ml cut off value derived from the ROC analysis are associated with a 
significantly lower overall survival (Log Rank, P=0.001) P values were determined using a Log-Rank test.
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0.917±0.084, p=0.007) than miR483 (AUC 0.875±0.081, 
p=0.006), Figure 2A and 2B. The best calculated cut-off 
values were 0.221 ng/ml, for miR483-5p (sensitivity=83.3% 
and specificity=100%), and 0.101 ng/ml, for miR483 
(sensitivity=87.5% and specificity=63.6%).
To assess the prognostic ability of miR483-5p and 
miR483 to predict recurrence-free and overall survival, we 
constructed Kaplan-Meier curves stratifying patients into 
two groups on the basis of the cut-off values determined 
by ROC analysis (0.101 ng/ml for miR483 and 0.221 ng/ml 
for miR483-5p). Of the two parameters, only miR483-5p 
was able to prognosticate recurrence-free (Figure 2C) and 
overall survival (Figure 2D).
To adjust for imbalances in the distribution of 
potential prognostic factors between comparisons of 
recurrence-free survival and overall survival, univariate 
and Cox models were fitted to the data. Age and sex were 
included as covariates together with the miR483-5p cut-
off level of 0.221 ng/ml. Tumor stage was not considered 
a covariate as it correlated with miR483-5p. On univariate 
analysis, only miR483-5p was associated with recurrence-
free survival (P=0.049) but not with overall survival 
(P=0.412) (Table 3). After adjustments for age and sex, 
the patients with circulating levels of miR483-5p ≥ 0.221 
ng/ml, maintained a significantly higher risk of recurrence 
(HR, 16.20; 95% confidence interval [CI], 1.39 to 188.6, 
P=0.026), Table 3.
Association between some parameters detected 
by the “liquid biopsy”: miR483-5p levels and 
circulating tumor cells
In a small group of patients (n=13), CTCs were 
isolated and counted in the same pre-S (n=9) and post-S 
(n=7) blood samples in which miR483 and miR483-5p 
levels had been measured. A significant positive correlation 
was found between CTCs and both miR483-5p (Figure 3A) 
and miR483 (Figure 3B).
DISCUSSION
The liquid biopsy is rapidly emerging as a powerful 
technique in oncology, not only for its diagnostic and 
prognostic uses, but also for monitoring the tumor 
progression through minimally invasive blood sampling. 
Interestingly, the liquid biopsy can provide important 
information on CTCs detached from the tumor mass, as 
well as on the molecular markers released by the tumor, 
such as circulating miR and free DNA.
miRs can be detected in blood samples of ACC 
patients paralleling the expression of the primary tumor [7, 
8]. Among those miRs differentially expressed in malignant 
and benign adrenal cortical tumor tissues, [2,3,8-10,12,15], 
miR483 and its mature variant miR483-5p, are detected at 
higher levels in blood from patients with ACC compared 
to ACA [12, 14]. Moreover, increased levels of miR483-5p 
and decreased levels of miR195, showed prognostic value 
in a cohort of 21 ACCs stratified into non-aggressive and 
aggressive cancers [12]. However, the sensitivity of the 
miR quantification technique used was low, as miR483-5p 
in serum samples of non-aggressive tumors was under the 
detection limit of the method and no cut-off value derived 
from ROC curves and used for recurrence or survival 
analysis was given. In addition, miR483 quantification 
was normalized with spiked-in RNA methodology using 
exogenously added Cel-miR-39 [12]. It is still under 
debate as to which is the most accurate method for miR 
normalization in qRT-PCR analysis, as no reliable and 
stable endogenous housekeeping miR has been defined so 
far [14, 16]. To overcome problems regarding normalization 
of miR plasma levels, which may affect the validity of 
diagnostic and prognostic tests based on circulating miR 
measurement, we developed an absolute quantification 
method for miRs. This method is based on qRT-PCR using 
a standard curve, and the amount of miRNA is quantified 
by capillary electrophoresis. The absolute quantification 
strategy adopted renders the assay independent from the 
reference genes and makes it suitable for measuring the 
specific target miR in repeated samples during disease 
monitoring. Moreover, the used reference material derived 
from a human ACC (H295R) cell line is expected to 
more closely resemble miR characteristics than artificial 
miRs used for spiking in previous studies [12, 17]. Using 
this method, miR483 and miR483-5p plasma levels were 
significantly different in high-risk (stages 3 and 4, according 
to ENS@T, 18) and low-risk ACCs (stages 1 and 2), 
or ACAs and normal adrenal. On ROC curve analysis, 
miR483-5p showed better accuracy (AUC) than miR483, 
with the best cut-off value of 0.221 ng/ml differentiating 
between the two ACC groups. This cut off-value represents 
a sensitivity of 83% and a specificity of 100% of the 
method. Due to the absolute quantification of miR483 in 
ACC plasma samples based on miR483 measurement 
obtained in H295R positive control, this novel method 
of miR483/miR483-5p detection is reproducible and not 
affected by the above-mentioned analytical problems. 
Interestingly, despite the positive correlation found between 
total miR483 and miR483-5p, the latter variant displayed 
a better discriminant power between low- and high-stage 
ACC groups. In a Cox multivariate regression analysis, 
miR483-5p remained the best prognostic variable for 
recurrence risk. Notably, miR483 maps at 11p15.5 within 
the second intron of the insulin-like growth factor 2 (IGF2) 
gene [7], which is one of the most hyper-expressed genes 
in ACC [7, 8, 19], and is involved, although apparently not 
being sufficient in promoting ACC in the mouse [20, 21], in 
the multistep progression process underlying the carcinoma 
development [22]. miR483-5p is one of the mature variants 
derived from the processing of miR483. It has been 
demonstrated to self-enhance miR483 transcription [23] and 
hyper-activate IGF2 expression, by directly binding the P2 
promoter of the IGF2 gene and decreasing its maternally-
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imprinted methylation [24]. Thus, miR483-5p represents 
one of the best markers for maintaining the self-fueling 
oncogenic activation of adrenocortical cancer cells.
Among the clinicopathologic parameters of ACC, 
only the tumor stage and diameter showed a positive 
correlation with miR483-5p. Likewise, we previously 
found a significant correlation of these two parameters 
with CTCs [23], one of the tumor markers obtainable 
from the liquid biopsy. CTC number and miR483-5p 
levels detected in the same blood samples of ACC patients 
showed a significant positive correlation. These findings 
validate not only the specific release of miR483 from 
the tumor mass (correlation with the diameter), but also 
the strict relationship between the corpuscular and the 
acellular part of the liquid biopsy.
Although our study confirms the reduction of miR483 
circulating levels previously observed after surgery [12], 
this decrease is not significant in our series, probably due 
to the high variability among subjects. Moreover, miR 
levels may remain high in the bloodstream at short times 
of follow up from surgery, due to the high stability of miRs 
in circulation even for long period. Indeed, nearly 40% of 
the post-surgery samples in our study has been drawn in 6 
months from surgery, when probably miRs derived from the 
tumor mass before surgery are still present.
Conversely, the statistically significant difference 
in miR483 and miR483-5p levels, detected between low 
and high stage groups before surgery, is also maintained 
at follow-up, suggesting that these miRs could be valuable 
markers of the tumor stage even in the long term. Moreover, 
the reduction observed after surgery and the correlation with 
the tumor diameter, further confirm specific release of miR 
from the tumor mass.
The main limitation of our study is the small cohort 
of ACC patients analyzed. However, ACC is a rare cancer, 
and our cohort of patients is well characterized according to 
the clinical data, and to date is the largest series analyzed for 
circulating miR483 and miR483-5p.
In conclusion, our study contributes to shed new 
light on the clinical diagnostic and prognostic power of 
miR483-5p detected in the bloodstream of patients with 
ACC. Furthermore, the quantitative method of absolute 
measurement of miR483-5p could be easily transferred to 
the routine analysis.
Table 3: mi483-5p levels is a predictive factors for the risk of recurrence/metastasis in ACC, Predictive factors for 
recurrence/metastasis are reported according to Univariate and Multivariate Cox Analyses. The model for the 
multivariate analysis includes age (continuous variable) and sex (dichotomized variable with male as the reference 
category), in addition to miR483-5p category (dichotomized variable with miR483-5p < 0.221 ng/ml as the reference 
category); stage has not been included as it correlates with miR483-5p levels. HR: hazard ratio; 95%CI: 95% 
confidence interval. Significant P values are indicated in italics.
Variable Univariate Multivariate
HR 95%CI P HR 95%CI P
miR483-5p 4.67 0.99-21.88 0.049 16.2 1.39-188.6 0.026
cut-off: 0.221 ng/ml
Age 1.03 0.97-1.10 0.277 1.02 0.96-1.08 0.522
Sex 1.03 0.26-4.11 0.971 0.65 0.98-4.23 0.654
Stage 2.43 0.97-6.08 0.58 - - -
Figure 3: Correlations between circulating levels of miR483 or miR483-5p, circulating tumor cells (CTC) and mitotane 
levels in ACC patients. CTC number positively correlates with miR483-5p (A) and miR483 (B) levels, as evaluated on the same 




The study included 40 patients affected by malignant 
(n=27 ACC) and benign (n=13 ACA) adrenocortical 
tumors, enrolled and evaluated at our University Hospital 
in Florence (AOU Careggi).
Plasma samples from healthy volunteers (n=10) were 
used as a control cohort of non-tumoral subjects for miR483 
assessment.
The study was approved by the Local Ethical 
Committee and written informed consent to participate was 
obtained from all patients.
Blood sample collection
For each subject, blood was collected in EDTA 
tubes, and plasma for miR extraction was obtained by 
centrifugation. In some patients (n=13) an additional 3 ml 
of total blood was processed within 3 hours after collection 
for CTC analysis.
Plasma separation
Plasma was separated from blood collected in EDTA 
tubes by two centrifugation steps of 10 minutes at 4°C: the 
first at 1,600g, the second at 16,000g. Plasma aliquots were 
stocked at -80°C.
RNA extraction
Reference RNA was extracted from the human cell 
line H295R by the miRNeasy Mini kit (Qiagen, Germany) 
following the protocol for Purification of Total RNA, 
including Small RNAs, from Animal Cells. Total cell-free 
RNA was extracted from 200 µl of plasma by using the 
miRNeasy mini kit, following the protocol for Purification 
of Total RNA, Including Small RNAs, from serum or 
plasma. Elution volume was 50 µl.
Quantification of miR483
Quantification of miR483 and miR483-5p in 
cell-free RNA was performed by real-time quantitative 
RT-PCR (qRT-PCR) using the Taqman Micro RNA 
Reverse Transcription kit (Life Technologies, USA) 
and the following Taqman Small RNA assays (Life 
Technologies, USA): hsa-miR483 and hsa-miR483-5p. 
RT and qPCR reactions were performed according to 
the manufacturer’s protocol on the instrument 7900HT 
(Life Technologies). Samples were quantified by using a 
reference curve expressed as the total amount of miRNA 
in the reference sample (total RNA from H295R cell 
line). The amount of miRNA in the reference sample 
was quantified by capillary electrophoresis using the 
kit Small RNA assay on the Agilent 2011 Bioanalyzer 
(Agilent Technologies, USA). The range of the standard 
curve was 0.00523-5.23-pg miRNA. The quantity of 
miR483 and miR483-5p was calculated by interpolating 
the Cq values of qPCR on the standard curve and 
expressed as total miRNA equivalents. The results were 
normalized for the volume of plasma and expressed as 
ng equivalents/ml plasma (abbreviated in text and figures 
as ng/ml).
CTC analysis
CTC analysis was performed on pre-surgery (n=9) 
and post-surgery (n=7) samples obtained from 13 patients 
with ACC, as previously described [25]. Briefly, the method 
consists of three sequential steps consisting of isolation 
of CTCs from blood by filtration on ScreenCell® Cyto 
filtration devices (ScreenCell, Paris, France), followed 
by identification through validated morphometric criteria 
[25-27] and cell count. Identification of adrenocortical 
cell origin was confirmed by immunocytochemistry 
using the polyclonal antibody against the adrenocortical 
marker steroidogenic factor 1 (SF-1, cat #07-618 Upstate, 
Millipore, Billerica, MA).
Histology and immunohistochemistry of the 
primary tumor
Histologic diagnosis was made by the referring 
pathologist on tumor tissue removed at surgery (ACC, 
n=27 and ACA, n=7). In 6 non-operated patients affected 
by non-functioning adrenal incidentaloma, the diagnosis of 
ACA was established based on the tumor characteristics by 
CT/MRI and unchanged imaging characteristics at least one 
year after diagnosis.
Tumor specimens were evaluated according to 
the Weiss system, which combines nine morphologic 
parameters: three related to tumor structure (description 
of cytoplasm, diffuse architecture and necrosis), three 
to cytology (atypia, atypical mitotic figures and mitotic 
count), and three to invasion (veins, sinusoids and tumor 
capsule). The presence of three or more criteria strongly 
correlates with malignant behavior [28].
Immunohistochemistry was performed on formalin-
fixed and paraffin-embedded tissues using antibodies 
directed against adrenocortical markers, such as SF-1, 
MART-1, inhibin-alpha and synaptophysin, to define 
the adrenocortical origin of the tumor [25]. Ki67 index 
was evaluated as a proliferation marker to assess ACC 
prognosis [29]. Immunohistochemical analysis with mouse 
anti-human Ki67 monoclonal MIB1 antibody (Dako) was 
carried out utilizing the Ventana Benchmark XT system 
(Ventana Medical Systems). Nuclei were hematoxylin-
counterstained, Ki67 positive nuclei were counted on 1,000 
tumor cells and Ki67 was expressed as the percentage of 
proliferating cells. Negative controls were achieved by 
omitting the primary antibody.
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Tumor stage was assessed according to the revised 
TNM classification of ACC proposed by the European 
Network for the Study of Adrenal Tumors (ENS@T) [18].
Statistical Analysis
All data was expressed as mean±SD. Statistical analysis 
was performed by SPSS 24.0 (Statistical Package for the Social 
Sciences, Chicago, USA) for Windows. The Kolmogorov–
Smirnov’s test was used to verify the normal distribution 
of data, which was expressed as mean ± SD. Differences in 
continuous variables were analyzed by means of Student’s t test 
for independent data to compare two classes of data. Univariate 
correlations were carried out using Pearson’s test. Receiver 
operating characteristic (ROC) curve analysis was performed 
to calculate AUC and select the miR483 and miR483-5p values 
showing the best sensitivity and specificity for discriminating 
between low (St 1/2) and high (St 3/4) disease stages. Survival 
(overall and recurrence-free) curves were computed according 
to the Kaplan–Meier analysis and were compared by means 
of the log-rank test. A Cox proportional-hazards regression 
analysis was used in univariate and multivariate analyses to 
assess the predictive role of miR483 or miR483-5p cut-off 
values on disease recurrence and overall survival. P<0.05 value 
was considered statistically significant.
Abbreviations
Adrenocortical carcinoma (ACC)
Circulating tumor cells (CTCs)
Insulin-like growth factor 2 (IGF2)
Micro RNA (miR)
Receiver Operator Characteristics (ROC)
Author contributions
F. Salvianti set up the quantitative miR method 
and performed miR analysis. L. Canu enrolled patients, 
collected patients’ clinical data and performed the clinical 
follow-up. G. Poli performed statistical analysis. R. 
Armignacco performed CTC detection and analysis. C. 
Scatena performed CTC detection and analysis. G. Cantini 
prepared the figures. A. Di Franco performed miR analysis. 
S. Gelmini performed miR analysis. T. Ercolino collected 
tumor specimens for the pathologist’s analysis. M. Pazzagli 
was the referent for the quantitative miR technological 
platform. G. Nesi was the referring pathologist. M. Mannelli 
was the referring clinician for the adrenal pathologies. P. 
Pinzani designed the study. M. Luconi designed the study, 
wrote the manuscript, obtained fundings. All authors had 
full access to all the data and had final responsibility for the 
decision to submit for publication.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest
FUNDINGS AND FELLOWSHIPS
The research leading to these results received funding 
from the Seventh Framework Programme (FP7/2007-2013) 
under grant agreement n° 259735 ENS@T-Cancer; and 
was supported by Associazione Italiana Ricerca sul Cancro 
(AIRC) Investigator Grant to M. L. (grant # IG2015-17691), 
where Dr. Giulia Cantini and Dr. Alessandra Di Franco were 
recipients of a research fellowship.
R.A.,G.C.,L.C,T.E., A.D.F.,M.M.,M.L., G.N. are 
members of the ENS@T (European Network for the Study 
of Adrenal Tumors).
REFERENCES
1. Terzolo M, Angeli A, Fassnacht M, Daffara F, 
Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, 
Grossrubatscher E, Reimondo G, Bollito E, Papotti M, et al. 
Adjuvant mitotane treatment for adrenocortical carcinoma. N 
Engl J Med. 2007;356:2372-80.
2. Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, 
Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-
Corail F, Elarouci N, Sbiera S, Kroiss M, et al. Integrated 
genomic characterization of adrenocortical carcinoma. Nat 
Genet. 2014;46:607-12.
3. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, 
Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello 
G, Kim S, Assie G, et al. Comprehensive Pan-Genomic 
Characterization of Adrenocortical Carcinoma. Cancer Cell. 
2016;29:723-36.
4. Alix-Panabières C, Pantel K. Clinical Applications of 
Circulating Tumor Cells and Circulating Tumor DNA as 
Liquid Biopsy. Cancer Discov. 2016;6:479-91.
5. Faillot S, Assie G. ENDOCRINE TUMOURS: The 
genomics of adrenocortical tumors. Eur J Endocrinol. 
2016;174:R249-65.
6. Gregory RI, Shiekhattar R. MicroRNA biogenesis and 
cancer. Cancer Res. 2005;65:3509-12.
7. Cherradi N. microRNAs as Potential Biomarkers in 
Adrenocortical Cancer: Progress and Challenges. Front 
Endocrinol (Lausanne). 2016 Jan 20;6:195. doi: 10.3389/
fendo.2015.00195. eCollection 2015.
8. Hassan N, Zhao JT, Sidhu SB. The role of microRNAs in 
the pathophysiology of adrenal tumors. Mol Cell Endocrinol. 
2016 Dec 20. pii: S0303-7207(16)30518-4. doi: 10.1016/j.
mce.2016.12.011. [Epub ahead of print]
9. Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, 
Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, 
Robinson BG, Sidhu SB. miR-195 and miR-483-5p Identified 
as Predictors of Poor Prognosis in Adrenocortical Cancer. 
Clin Cancer Res.2009;15:7684-7692.
10. Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E. 
MicroRNA profiling of adrenocortical tumors reveals miR-
483 as a marker of malignancy. Cancer. 2011;117:1630-9.
Oncotarget9www.impactjournals.com/oncotarget
11. Duregon E, Rapa I, Votta A, Giorcelli J, Daffara F, Terzolo 
M, Scagliotti GV, Volante M, Papotti M. MicroRNA 
expression patterns in adrenocortical carcinoma variants 
and clinical pathologic correlations. Hum Pathol. 
2014;45:1555-62.
12. Chabre O, Libé R, Assie G, Barreau O, Bertherat J, Bertagna 
X, Feige JJ, Cherradi N. Serum miR-483-5p and miR-195 are 
predictive of recurrence risk in adrenocortical cancer patients. 
Endocr Relat Cancer. 2013;20:579-94.
13. Patel D, Boufraqech M, Jain M, Zhang L, He M, Gesuwan 
K, et al. MiR-34a and miR-483-5p are candidate serum 
biomarkers for adrenocortical tumors. Surgery [Internet]. 
2013
14. Szabó DR, Luconi M, Szabó PM, Tóth M, Szücs N, Horányi 
J, Nagy Z, Mannelli M, Patócs A, Rácz K, Igaz P. Analysis of 
circulating microRNAs in adrenocortical tumors. Lab Invest. 
2014;94:331-9.
15. Özata DM, Caramuta S, Velázquez-Fernández D, Akçakaya 
P, Xie H, Höög A, Zedenius J, Bäckdahl M, Larsson C, Lui 
WO. The role of microRNA deregulation in the pathogenesis 
of adrenocortical carcinoma. Endocr Relat Cancer. 
2011;18:643-55.
16. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman 
SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom 
J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher 
CW, et al. Circulating microRNAs as stable blood-based 
markers for cancer detection. Proc Natl Acad Sci U S A. 
2008;105:10513-8.
17. Roberts TC, Coenen-Stass AM, Wood MJ. Assessment of 
RT-qPCR normalization strategies for accurate quantification 
of extracellular microRNAs in murine serum. PLoS One. 
2014;9:e89237.
18. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg 
HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio 
B; German Adrenocortical Carcinoma Registry Group.; 
European Network for the Study of Adrenal Tumors. Limited 
prognostic value of the 2004 International Union Against 
Cancer staging classification for adrenocortical carcinoma: 
proposal for a Revised TNM Classification. Cancer. 
2009;115:243-50.
19. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, 
Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson 
NW, Taylor JM, Hanash SM. Distinct transcriptional profiles 
of adrenocortical tumors uncovered by DNA microarray 
analysis. Am J Pathol. 2003;162:521-31.
20. Drelon C, Berthon A, Ragazzon B, Tissier F, Bandiera 
R, Sahut-Barnola I, de Joussineau C, Batisse-Lignier M, 
Lefrançois-Martinez AM, Bertherat J, Martinez A, Val P. 
Analysis of the role of Igf2 in adrenal tumour development 
in transgenic mouse models. PLoS One. 2012;7:e44171.
21. Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, 
Almeida MQ, Fragoso MC, Kuick R, Lerario AM, Simon DP, 
Soares IC, Starnes E, Thomas DG, Latronico AC, Giordano 
TJ, Hammer GD. Progression to adrenocortical tumorigenesis 
in mice and humans through insulin-like growth factor 2 and 
β-catenin. Am J Pathol. 2012;181:1017-33.
22. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin 
E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, 
Plouin PF, Luton JP, Le Bouc Y. Molecular markers and long-
term recurrences in a large cohort of patients with sporadic 
adrenocortical tumors. Cancer Res. 2001;61:6762-7.
23. Emmerling VV, Fischer S, Kleemann M, Handrick R, 
Kochanek S, Otte K. miR-483 is a self-regulating microRNA 
and can activate its own expression via USF1 in HeLa cells. 
Int J Biochem Cell Biol. 2016;80:81-86.
24. Zhang Y, Hu JF, Wang H, Cui J, Gao S, Hoffman AR, Li 
W. CRISPR Cas9-guided chromatin immunoprecipitation 
identifies miR483 as an epigenetic modulator of IGF2 
imprinting in tumors. Oncotarget. 2016 Jul 29. doi: 10.18632/
oncotarget.10918. [Epub ahead of print].
25. Pinzani P, Scatena C, Salvianti F, Corsini E, Canu L, Poli G, 
Paglierani M, Piccini V, Pazzagli M, Nesi G, Mannelli M, 
Luconi M. Detection of circulating tumor cells in patients 
with adrenocortical carcinoma: a monocentric preliminary 
study. J Clin Endocrinol Metab. 2013;98:3731-8.
26. De Giorgi V, Pinzani P, Salvianti F, Panelos J, Paglierani M, 
Janowska A, Grazzini M, Wechsler J, Orlando C, Santucci M, 
Lotti T, Pazzagli M, Massi D. Application of a filtration- and 
isolation-by-size technique for the detection of circulating 
tumor cells in cutaneous melanoma. J Invest Dermatol. 
2010;130:2440-7.
27. Mascalchi M, Falchini M, Maddau C, Salvianti F, Nistri 
M, Bertelli E, Sali L, Zuccherelli S, Vella A, Matucci M, 
Voltolini L, Pegna AL, Luconi M, et al. Prevalence and 
number of circulating tumour cells and microemboli at 
diagnosis of advanced NSCLC. J Cancer Res Clin Oncol. 
2016;142:195-200.
28. Lau SK, Weiss LM. The Weiss system for evaluating 
adrenocortical neoplasms: 25 years later. Hum Pathol. 
2009;40:757-68.
29. Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, 
Tanemoto M, Abe M, Uruno A, Ishidoya S, Arai Y, Takahashi 
K, Sasano H, Ito S. Immunohistochemistry of a proliferation 
marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 
labeling index is a predictor for recurrence of adrenocortical 
carcinomas. Endocr J. 2008;55:49-55.
